Oruka Therapeutics, Inc. (NASDAQ:ORKA) is Fairmount Funds Management LLC's 8th Largest Position

Fairmount Funds Management LLC lifted its holdings in Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) by 5.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,371,922 shares of the company's stock after buying an additional 160,000 shares during the period. Oruka Therapeutics comprises approximately 6.5% of Fairmount Funds Management LLC's portfolio, making the stock its 8th biggest position. Fairmount Funds Management LLC owned about 9.63% of Oruka Therapeutics worth $65,382,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. JPMorgan Chase & Co. purchased a new stake in shares of Oruka Therapeutics during the fourth quarter worth $54,000. AlphaCentric Advisors LLC acquired a new stake in Oruka Therapeutics during the fourth quarter worth about $119,000. China Universal Asset Management Co. Ltd. acquired a new stake in Oruka Therapeutics during the fourth quarter worth about $144,000. Charles Schwab Investment Management Inc. acquired a new stake in Oruka Therapeutics during the fourth quarter worth about $303,000. Finally, Geode Capital Management LLC acquired a new stake in Oruka Therapeutics during the third quarter valued at approximately $343,000. 56.44% of the stock is currently owned by hedge funds and other institutional investors.

Oruka Therapeutics Trading Down 0.3%

ORKA stock traded down $0.03 during mid-day trading on Tuesday, hitting $9.72. 52,279 shares of the company were exchanged, compared to its average volume of 229,933. The business has a 50 day simple moving average of $9.93 and a 200-day simple moving average of $15.23. The stock has a market capitalization of $363.93 million, a PE ratio of -1.55 and a beta of 0.25. Oruka Therapeutics, Inc. has a 1-year low of $5.49 and a 1-year high of $31.13.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last announced its quarterly earnings data on Thursday, March 6th. The company reported ($0.49) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.68) by $0.19. Equities research analysts expect that Oruka Therapeutics, Inc. will post -3.41 earnings per share for the current year.

Insiders Place Their Bets

In other Oruka Therapeutics news, major shareholder Venrock Healthcare Capital Par purchased 88,794 shares of the firm's stock in a transaction on Friday, February 14th. The stock was purchased at an average cost of $11.44 per share, for a total transaction of $1,015,803.36. Following the acquisition, the insider now owns 4,148,428 shares in the company, valued at approximately $47,458,016.32. The trade was a 2.19% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 22.67% of the company's stock.

Analyst Upgrades and Downgrades

ORKA has been the topic of a number of recent research reports. HC Wainwright reaffirmed a "buy" rating and set a $45.00 price objective on shares of Oruka Therapeutics in a report on Friday, February 7th. Wolfe Research assumed coverage on shares of Oruka Therapeutics in a research report on Tuesday, February 4th. They issued an "outperform" rating and a $20.00 price objective for the company. Finally, Wedbush reiterated an "outperform" rating and set a $40.00 target price on shares of Oruka Therapeutics in a report on Friday, March 7th. Seven research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and an average target price of $39.86.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.